PL1673104T5 - Dostarczanie związków terapeutycznych do mózgu i do innych tkanek - Google Patents

Dostarczanie związków terapeutycznych do mózgu i do innych tkanek

Info

Publication number: PL1673104T5
Authority: PL; Poland
Prior art keywords: brain; tissues; delivery; therapeutic compounds; therapeutic
Prior art date: 2003-08-29

Application number

PL04782579.9T

Other languages

English (en)

Other versions

PL1673104T3 (pl

Inventor

Emil D. Kakkis

Original Assignee

Biomarin Pharmaceutical Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-29

Filing date

2004-08-30

Publication date

2023-03-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34217412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1673104(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2004-08-30 Application filed by Biomarin Pharmaceutical Inc. filed Critical Biomarin Pharmaceutical Inc.

2014-03-31 Publication of PL1673104T3 publication Critical patent/PL1673104T3/pl

2023-03-06 Publication of PL1673104T5 publication Critical patent/PL1673104T5/pl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06008—Cerebroside-sulfatase (3.1.6.8)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0105—Alpha-N-acetylglucosaminidase (3.2.1.50)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Orthopedic Medicine & Surgery (AREA)
Psychology (AREA)
Hematology (AREA)
Obesity (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PL04782579.9T 2003-08-29 2004-08-30 Dostarczanie związków terapeutycznych do mózgu i do innych tkanek PL1673104T5 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US10/651,493 US7442372B2 (en)	2003-08-29	2003-08-29	Delivery of therapeutic compounds to the brain and other tissues
PCT/US2004/028135 WO2005021064A2 (en)	2003-08-29	2004-08-30	Delivery of therapeutic compounds to the brain and other tissues
EP04782579.9A EP1673104B2 (en)	2003-08-29	2004-08-30	Delivery of therapeutic compounds to the brain and other tissues

Publications (2)

Publication Number	Publication Date
PL1673104T3 PL1673104T3 (pl)	2014-03-31
PL1673104T5 true PL1673104T5 (pl)	2023-03-06

Family

ID=34217412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL04782579.9T PL1673104T5 (pl)	2003-08-29	2004-08-30	Dostarczanie związków terapeutycznych do mózgu i do innych tkanek

Country Status (12)

Country	Link
US (5)	US7442372B2 (pl)
EP (1)	EP1673104B2 (pl)
JP (1)	JP5819574B2 (pl)
AU (1)	AU2004268645B2 (pl)
CA (1)	CA2537238C (pl)
CY (1)	CY1114815T1 (pl)
DK (1)	DK1673104T4 (pl)
ES (1)	ES2441612T5 (pl)
PL (1)	PL1673104T5 (pl)
PT (1)	PT1673104E (pl)
SI (1)	SI1673104T2 (pl)
WO (1)	WO2005021064A2 (pl)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6585971B1 (en) *	1999-11-12	2003-07-01	Harbor-Ucla Research And Education Institute	Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US7723296B2 (en)	2001-01-18	2010-05-25	Genzyme Corporation	Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7560424B2 (en)	2001-04-30	2009-07-14	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7629309B2 (en)	2002-05-29	2009-12-08	Zystor Therapeutics, Inc.	Targeted therapeutic proteins
US7442372B2 (en)	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
US20050208090A1 (en) *	2004-03-18	2005-09-22	Medtronic, Inc.	Methods and systems for treatment of neurological diseases of the central nervous system
CA2568150A1 (en) *	2004-06-21	2006-01-05	Medtronic, Inc.	Medical systems and methods for delivering compositions to cells
AR059089A1 (es)	2006-01-20	2008-03-12	Genzyme Corp	Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
MX358492B (es)	2006-02-09	2018-08-22	Genzyme Corp Star	Suministro intraventricular lento.
EP2046435A4 (en) *	2006-07-13	2012-06-27	Medtronic Inc	METHOD AND FORMULATIONS FOR OPTIMAL LOCAL ADMINISTRATION OF CELL THERAPY BY MEANS OF MINIMALLY INVASIVE PROCEDURES
US8849372B2 (en) *	2006-11-22	2014-09-30	The General Hospital Corporation	Method for magnetic resonance imaging using stimulus induced rotary saturation with a contrast agent
WO2008070769A1 (en) *	2006-12-06	2008-06-12	Medtronic, Inc.	Intrathecal catheter
CN102978185B (zh)	2007-01-18	2015-02-11	建新公司	包含氨基氧基基团的寡糖及其轭合物
WO2008089339A2 (en) *	2007-01-18	2008-07-24	Genzyme Corporation	Oligosaccharide conjugates for cellular targeting
ES2635726T3 (es) *	2007-06-06	2017-10-04	Genzyme Corporation	Terapia génica para enfermedades de almacenamiento lisosómico
US8702640B2 (en)	2007-08-17	2014-04-22	The Invention Science Fund I, Llc	System, devices, and methods including catheters configured to monitor and inhibit biofilm formation
US20090048648A1 (en) *	2007-08-17	2009-02-19	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Self-sterilizing device
US8734718B2 (en)	2007-08-17	2014-05-27	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having an actively controllable therapeutic agent delivery component
US9005263B2 (en)	2007-08-17	2015-04-14	The Invention Science Fund I, Llc	System, devices, and methods including actively-controllable sterilizing excitation delivery implants
US8460229B2 (en)	2007-08-17	2013-06-11	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having components that are actively controllable between transmissive and reflective states
US8162924B2 (en)	2007-08-17	2012-04-24	The Invention Science Fund I, Llc	System, devices, and methods including actively-controllable superoxide water generating systems
US8114346B2 (en) *	2007-08-17	2012-02-14	The Invention Science Fund I, Llc	Event-triggered ultraviolet light sterilization of surfaces
US8366652B2 (en)	2007-08-17	2013-02-05	The Invention Science Fund I, Llc	Systems, devices, and methods including infection-fighting and monitoring shunts
US8753304B2 (en)	2007-08-17	2014-06-17	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having acoustically actuatable waveguide components for delivering a sterilizing stimulus to a region proximate a surface of the catheter
US8647292B2 (en)	2007-08-17	2014-02-11	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having components that are actively controllable between two or more wettability states
US8706211B2 (en)	2007-08-17	2014-04-22	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters having self-cleaning surfaces
US8029740B2 (en) *	2008-07-11	2011-10-04	The Invention Science Fund I, Llc	Event-triggered self-sterilization of article surfaces
AU2008290217B2 (en) *	2007-08-20	2013-09-05	Protalix Ltd.	Saccharide-containing protein conjugates and uses thereof
JP5584132B2 (ja) *	2007-11-15	2014-09-03	ザユニバーシティオブノースカロライナアットチャペルヒル	疼痛の治療のための前立腺酸性ホスファターゼ
ES2629853T3 (es)	2008-05-07	2017-08-16	Biomarin Pharmaceutical Inc.	Péptidos de dirección lisosómica y usos de los mismos
US20110295088A1 (en)	2008-12-04	2011-12-01	Searete Llc, A Limited Liability Corporation Of The State Of Delaware	Systems, devices, and methods including implantable devices with anti-microbial properties
US8585627B2 (en)	2008-12-04	2013-11-19	The Invention Science Fund I, Llc	Systems, devices, and methods including catheters configured to monitor biofilm formation having biofilm spectral information configured as a data structure
MX364498B (es)	2008-12-16	2019-04-29	Genzyme Corp	Conjugados de oligosacáridos-protenías.
ES2758827T3 (es)	2009-06-17	2020-05-06	Biomarin Pharm Inc	Formulaciones para enzimas lisosómicas
IL314807A (en) *	2009-08-28	2024-10-01	Icahn School Med Mount Sinai	Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US9194011B2 (en)	2009-11-17	2015-11-24	Protalix Ltd.	Stabilized alpha-galactosidase and uses thereof
NZ605874A (en) *	2010-06-25	2015-02-27	Shire Human Genetic Therapies	Methods and compositions for cns delivery of heparan n-sulfatase
AU2011270670B2 (en) *	2010-06-25	2017-01-12	Takeda Pharmaceutical Company Limited	Methods and compositions for CNS delivery of arylsulfatase A
EP3103469B1 (en) *	2010-06-25	2020-12-09	Shire Human Genetic Therapies, Inc.	Cns delivery of therapeutic agents
PE20130648A1 (es) *	2010-06-25	2013-07-03	Shire Human Genetic Therapies	Tratamiento del sindrome de sanfilippo tipo b
WO2011163651A2 (en) *	2010-06-25	2011-12-29	Shire Human Genetic Therapies, Inc.	METHODS AND COMPOSITIONS FOR CNS DELIVERY OF β-GALACTOCEREBROSIDASE
AU2011270672B2 (en) *	2010-06-25	2017-01-12	Shire Human Genetic Therapies, Inc.	Treatment of Sanfilippo Syndrome type B
KR20230159646A (ko) *	2010-06-25	2023-11-21	샤이어 휴먼 지네틱 테라피즈 인크.	이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
JP2012062312A (ja) *	2010-08-19	2012-03-29	Yoshikatsu Eto	ハンター症候群の治療剤
US9732333B2 (en)	2011-01-20	2017-08-15	Protalix Ltd.	Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells
WO2013055888A2 (en) *	2011-10-12	2013-04-18	Synageva Biopharma Corp.	Recombinant human naglu protein and uses thereof
US9101678B2 (en)	2011-11-03	2015-08-11	Elwha Llc	Heat-sanitization of surfaces
EP2776553B1 (en) *	2011-11-07	2018-07-11	Shire Human Genetic Therapies, Inc.	Biomarkers for sanfilippo syndrome and uses thereof
EP3711778B1 (en) *	2011-12-02	2024-05-08	Armagen, Inc.	Methods and compositions for increasing arylsulfatase a activity in the cns
US20140377244A1 (en)	2011-12-23	2014-12-25	Shire Human Genetic Therapies, Inc.	Stable formulations for cns delivery of arylsulfatase a
AU2012358223B2 (en) *	2011-12-23	2018-01-18	Takeda Pharmaceutical Company Limited	Treatment of cognitive impairment of Hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
EP2880156B1 (en) *	2012-07-31	2017-08-23	biOasis Technologies Inc	Dephosphorylated lysosomal storage disease proteins and methods of use thereof
CN107865968B (zh) *	2012-08-03	2021-03-05	美国政府(由卫生和人类服务部的部长所代表)	用于治疗溶酶体贮积症的环糊精
HRP20181351T1 (hr)	2012-11-27	2018-11-02	Biomarin Pharmaceutical Inc.	Ciljani terapeutski fuzijski proteini lizosomalnog enzima i njihova uporaba
HK1214961A1 (zh) *	2012-12-07	2016-08-12	Shire Human Genetic Therapies, Inc.	粘多醣病iiia型的鞘內注射治療的方法和組合物
EP2981551B1 (en)	2013-02-20	2020-06-03	Valerion Therapeutics, LLC	Methods and compositions for treatment of pompe disease
AU2014265417B2 (en) *	2013-05-15	2018-07-26	Regenxbio Inc.	Adeno-associated virus mediated gene transfer to the central nervous system
US9994641B2 (en)	2013-12-25	2018-06-12	Jcr Pharmaceuticals Co., Ltd.	Anti-human transferrin receptor antibody that passes through blood-brain barrier
TWI752907B (zh)	2015-05-08	2022-01-21	美商拜奧馬林製藥公司	用於治療cln2疾病之tpp1調配物及方法
HK1247856A1 (zh)	2015-06-10	2018-10-05	Vtesse, Inc.	羟丙基β-环糊精组合物及方法
US11248045B2 (en)	2015-06-24	2022-02-15	Jcr Pharmaceuticals Co., Ltd.	Anti-human transferrin receptor antibody permeating blood-brain barrier
KR20180020279A (ko)	2015-06-24	2018-02-27	제이씨알 파마 가부시키가이샤	Bdnf를 포함하는 융합 단백질
CN108474788A (zh)	2015-11-06	2018-08-31	生物马林药物股份有限公司	用于检测中和溶酶体酶的摄取的抗体或其它因子的基于细胞的测定
MX2018010196A (es)	2016-02-24	2018-11-19	Biomarin Pharm Inc	Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas.
US11253612B2 (en)	2016-04-15	2022-02-22	The Trustees Of The University Of Pennsylvania	Gene therapy for treating mucopolysaccharidosis type II
JP7079243B2 (ja) *	2016-06-02	2022-06-01	エイディーエスセラピューティクスリミテッドライアビリティカンパニー	緑内障手術の成功率を向上させるためにニンテダニブを使用する組成物および方法
JP2019517274A (ja)	2016-06-13	2019-06-24	ザユニバーシティオブノースカロライナアットチャペルヒルＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＮｏｒｔｈＣａｒｏｌｉｎａＡｔＣｈａｐｅｌＨｉｌｌ	最適化されたｃｌｎ１遺伝子および発現カセットおよびそれらの使用
TWI761413B (zh)	2016-12-26	2022-04-21	日商Ｊｃｒ製藥股份有限公司	通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
EP3561058B1 (en)	2016-12-26	2025-07-23	JCR Pharmaceuticals Co., Ltd.	Fusion protein including bdnf
US11723865B2 (en)	2017-02-08	2023-08-15	New Hope Research Foundation, Inc.	Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
US11541005B2 (en)	2017-02-08	2023-01-03	New Hope Research Foundation, Inc.	Systems and methods for enhanced distribution of a biologic agent within the brain and spinal cord
TWI835747B (zh)	2017-09-22	2024-03-21	賓州大學委員會	用於治療黏多醣病 ii 型之基因治療
KR20200058510A (ko)	2017-10-02	2020-05-27	데날리 테라퓨틱스 인크.	효소 대체 요법 효소를 포함하는 융합 단백질
CN110402285A (zh) *	2018-02-23	2019-11-01	再生生物医疗公司	用于将干细胞和药物滴注入人脑室系统的方法、装置和系统
US12018087B2 (en)	2018-08-02	2024-06-25	Dyne Therapeutics, Inc.	Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en)	2018-08-02	2024-09-24	Dyne Therapeutics, Inc.	Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3830259A4 (en)	2018-08-02	2022-05-04	Dyne Therapeutics, Inc.	MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
EP3670652A1 (en) *	2018-12-18	2020-06-24	NEUWAY Pharma GmbH	Vlp for the treatment of a lysosomal storage disease
JP6884432B2 (ja) *	2018-12-18	2021-06-09	ノイウェイファルマゲーエムベーハー	新規薬物送達システムおよびそれを提供する方法
CN113301925A (zh)	2018-12-19	2021-08-24	小利兰·斯坦福大学理事会	用于溶酶体靶向的双官能分子以及相关的组合物和方法
US11446084B2 (en)	2019-07-12	2022-09-20	Neuralink Corp.	Laser drilling of pia mater
BR112022003598A2 (pt)	2019-08-29	2022-05-24	Biomarin Pharm Inc	Métodos para tratamento da doença cln2 em indivíduos pediátricos
JP2023512281A (ja)	2020-02-03	2023-03-24	ゲインセラピューティクスエスアー	Ｍｐｓ１を処置するための併用療法
KR102880902B1 (ko)	2021-01-29	2025-11-03	현대자동차주식회사	셀 기반 모빌리티 생산시스템의 운영방법
US20240043473A1 (en) *	2021-02-09	2024-02-08	Phoenix Nest Inc.	Nootropic peptides for treating lysosomal storage diseases
WO2023288033A1 (en)	2021-07-14	2023-01-19	Lycia Therapeutics, Inc.	Asgpr cell surface receptor binding compounds and conjugates
US11958917B2 (en)	2022-02-18	2024-04-16	Beren Therapeutics P.B.C.	Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
WO2025125542A1 (en) *	2023-12-15	2025-06-19	F. Hoffmann-La Roche Ag	Intrathecal dosage method

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2601215A (en)	1948-03-17	1952-06-17	American Cyanamid Co	Process of preparing dihydropterins
US3505329A (en)	1968-02-06	1970-04-07	Smithkline Corp	Process for the synthesis of biopterin
JPS5883691A (ja)	1981-11-13	1983-05-19	Kanegafuchi Chem Ind Co Ltd	１′，２′−ジアシル−（６ｒ，ｓ）−５，６，７，８−テトラヒドロ−ｌ−ビオプテリンおよびその製法
JPS5925323A (ja)	1982-03-03	1984-02-09	鐘淵化学工業株式会社	プテリン誘導体からなる脳内神経伝達物質の関わる疾病の治療剤
CH651755A5 (en)	1982-03-03	1985-10-15	Kanegafuchi Chemical Ind	Use of pterin derivatives
ZA836957B (en)	1982-09-20	1985-04-24	Wellcome Found	Neurologically active chemical compounds
GB8318833D0 (en)	1983-07-12	1983-08-10	Wellcome Found	Chemical compounds
US5196533A (en)	1983-04-11	1993-03-23	South Alabama Medical Science Foundation, Usa	Cyclization of 5 amino-pyrimidines to quinoid 6,6 disubstituted dihydropteridines
US4587340A (en)	1983-09-19	1986-05-06	Burroughs Wellcome Co.	Biopterin analogs
JPS60178887A (ja)	1984-02-23	1985-09-12	Kanegafuchi Chem Ind Co Ltd	５，６，７，８−テトラヒドロ−ｌ−ビオプテリンの製造法
JPS60199889A (ja)	1984-03-24	1985-10-09	Kanegafuchi Chem Ind Co Ltd	５，６，７，８−テトラヒドロ−ｌ−エリスロ−ビオプテリンの硫酸塩およびその製法
US4550109A (en)	1984-05-31	1985-10-29	The Board Of Regents, The University Of Texas System	Lipoidal biopterin compounds
DE3437944A1 (de)	1984-10-17	1986-07-31	Biotest-Serum-Institut Gmbh, 6000 Frankfurt	Verwendung von pterinen zur steigerung der aktivitaet von lymphokinen und anderen blutfaktoren, sowie ein diagnostisches oder therapeutisches praeparat, das pterine in kombination mit lymphokinen enthaelt
US4713454A (en)	1985-01-28	1987-12-15	Shiratori Pharmaceutical Co., Ltd.	Preparation process of (6R)-tetrahydro-L-biopterin
JPS61277618A (ja)	1985-06-04	1986-12-08	Suntory Ltd	自閉症治療剤
US4801575A (en) *	1986-07-30	1989-01-31	The Regents Of The University Of California	Chimeric peptides for neuropeptide delivery through the blood-brain barrier
EP0318926B1 (en)	1987-11-30	1995-05-03	Kabushiki Kaisha Vitamin Kenkyusyo	Intermediates for synthesizing 5,6,7,8-tetrahydro-L-erythro-biopterin and its derivatives
US6149909A (en)	1995-06-23	2000-11-21	Women's And Children's Hospital	Synthetic α-L-iduronidase and genetic sequences encoding same
JP2534423B2 (ja)	1991-12-26	1996-09-18	コーネル・リサーチ・ファンデーション・インコーポレイテッド	酸化窒素の過剰生産から生じる血管失調を阻止する阻害剤
US5198547A (en)	1992-03-16	1993-03-30	South Alabama Medical Science Foundation, Usa	Process for N5-formylating tetrahydropteridines
US5981194A (en)	1992-07-10	1999-11-09	University Of British Columbia	Use of p97 and iron binding proteins as diagnostic and therapeutic agents
DE4308739C1 (de)	1993-03-19	1994-06-23	Henning Berlin Gmbh	Pterinderivate, ihre Herstellung und ihre Verwendung
US5945452A (en)	1993-06-11	1999-08-31	The Board Of Trustees Of The Leland Stanford Junior University	Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5502050A (en)	1993-11-29	1996-03-26	Cornell Research Foundation, Inc.	Blocking utilization of tetrahydrobiopterin to block induction of nitric oxide synthesis
EP0722731B1 (en)	1994-08-05	2002-06-05	Suntory Limited	Remedy for spinocerebellar degeneration
US5716614A (en) *	1994-08-05	1998-02-10	Molecular/Structural Biotechnologies, Inc.	Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5929304A (en)	1995-09-14	1999-07-27	Croptech Development Corporation	Production of lysosomal enzymes in plant-based expression systems
US6002067A (en)	1996-05-20	1999-12-14	The University Of British Columbia	Transgenic mouse model for iduronidase deficiency and methods of making and using same
US20020076782A1 (en)	1996-07-05	2002-06-20	John P.N. Rosazza	Purified nitric oxide synthase
GB9617990D0 (en)	1996-08-29	1996-10-09	Scotia Holdings Plc	Treatment of pain
US6458574B1 (en) *	1996-09-12	2002-10-01	Transkaryotic Therapies, Inc.	Treatment of a α-galactosidase a deficiency
US5922713A (en)	1997-06-26	1999-07-13	Werner; Ernst	Inhibition of nitric oxide synthase
JP4306825B2 (ja)	1998-02-27	2009-08-05	アスビオファーマ株式会社	インスリン抵抗性が関与する血管機能異常を伴う疾患の予防または治療剤
CN1300323A (zh) *	1998-05-13	2001-06-20	加州大学洛杉矶分校港口研究和教育院	重组α－L－艾杜糖苷酸酶,其生产和纯化的方法以及治疗其缺乏导致的疾病的方法
US6200758B1 (en)	1999-02-19	2001-03-13	New York State Office Of Mental Health	Phenylalanine hydroxylase gene variants, and amino acid and pterin homeostasis, in the definition, detection, treatment and prevention of psychotic, mood and personality disorders
US6217552B1 (en)	1999-03-01	2001-04-17	Coaxia, Inc.	Medical device for selective intrathecal spinal cooling in aortic surgery and spinal trauma
US6521212B1 (en)	1999-03-18	2003-02-18	United Therapeutics Corporation	Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
EP1175210A4 (en)	1999-03-19	2003-07-09	Enos Pharmaceuticals Inc	STRENGTHENING THE BIODAVAILABILITY OF DRUGS IN THE BRAIN
US6642038B1 (en)	1999-09-14	2003-11-04	Genzyme Glycobiology Research Institute, Inc.	GlcNAc phosphotransferase of the lysosomal targeting pathway
GB2355191A (en)	1999-10-12	2001-04-18	Laxdale Ltd	Combination formulations for fatigue, head injury and strokes
US6569661B1 (en)	1999-11-12	2003-05-27	Biomarin Pharmaceutical Inc.	Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US6585971B1 (en)	1999-11-12	2003-07-01	Harbor-Ucla Research And Education Institute	Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
US6426208B1 (en)	1999-11-12	2002-07-30	Harbor-Ucla Research And Education Institute	Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
CA2388807C (en) *	1999-11-12	2013-08-06	Matthew C. Coffey	Viruses for the treatment of cellular proliferative disorders
US6582692B1 (en) *	1999-11-17	2003-06-24	Avigen, Inc.	Recombinant adeno-associated virus virions for the treatment of lysosomal disorders
US6972124B2 (en) *	2000-05-01	2005-12-06	Biomarin Pharmaceuticals Inc.	Precursor of N-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
US20020006400A1 (en)	2000-05-11	2002-01-17	Peter Lobel	Recombinant human CLN2 protein and methods of its production and use
US6544994B2 (en)	2000-06-07	2003-04-08	Eprov Ag	Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase
US20020095135A1 (en) *	2000-06-19	2002-07-18	David Meeker	Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
EP1301201B1 (en)	2000-07-18	2007-02-28	Duke University	Treatment of glycogen storage disease type ii
US20050119270A1 (en)	2000-08-04	2005-06-02	Mason R. P.	Synergistic effect of amlodipine and atorvastatin on aortic endothelial cell nitric oxide release
AU2001280215B9 (en)	2000-08-31	2007-03-22	Asubio Pharma Co., Ltd.	Process for Production of Biopterin Compound
JP4641705B2 (ja) *	2001-04-30	2011-03-02	ザイストールセラピューティクス，インコーポレイテッド	治療的タンパク質の亜細胞標的化
AU2002317700A1 (en) †	2001-06-07	2002-12-16	Hemebiotech A/S	Production of recombinant human arylsulfatase a
US20030007961A1 (en)	2001-06-22	2003-01-09	Wilburn Michael D.	Orthomolecular vitamin E derivatives
US20030072761A1 (en) †	2001-10-16	2003-04-17	Lebowitz Jonathan	Methods and compositions for targeting proteins across the blood brain barrier
US7658916B2 (en)	2002-04-05	2010-02-09	Genzyme Corporation	Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US20030198620A1 (en)	2002-04-16	2003-10-23	Keiya Ozawa	Method of treating amino acid metabolic disorders using recombinant adeno-associated virus virions
CA2483270C (en)	2002-04-25	2015-03-31	Transkaryotic Therapies, Inc.	Treatment of alpha-galactosidase a deficiency
US7485314B2 (en)	2002-05-06	2009-02-03	Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center	Induction of antigen specific immunologic tolerance
US20050142141A1 (en)	2002-11-27	2005-06-30	Pardridge William M.	Delivery of enzymes to the brain
DE10260263A1 (de)	2002-12-20	2004-07-15	Biocrates Life Sciences Gmbh	Verwendung von Tetrahydrobiopterinderivaten zur Behandlung und Ernährung von Patienten mit Aminosäurestoffwechselstörungen
EP1613264A4 (en)	2003-04-16	2007-08-15	Yeda Res & Dev	MEDICAMENT FOR THE TREATMENT OF GAUCHER DISEASE AND METHOD FOR IDENTIFYING IT
US20050026823A1 (en) *	2003-06-20	2005-02-03	Biomarin Pharmaceutical Inc.	Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
JP5624256B2 (ja) *	2003-06-20	2014-11-12	ラプター・ファーマシューティカル・インコーポレイテッド	脳および他の組織への治療化合物の送達
US7442372B2 (en) *	2003-08-29	2008-10-28	Biomarin Pharmaceutical Inc.	Delivery of therapeutic compounds to the brain and other tissues
US8003126B2 (en)	2004-11-17	2011-08-23	Biomarin Pharmaceutical Inc.	Stable tablet formulation

2003
- 2003-08-29 US US10/651,493 patent/US7442372B2/en not_active Expired - Lifetime
2004
- 2004-08-30 DK DK04782579.9T patent/DK1673104T4/da active
- 2004-08-30 WO PCT/US2004/028135 patent/WO2005021064A2/en not_active Ceased
- 2004-08-30 SI SI200432119T patent/SI1673104T2/sl unknown
- 2004-08-30 PT PT47825799T patent/PT1673104E/pt unknown
- 2004-08-30 ES ES04782579T patent/ES2441612T5/es not_active Expired - Lifetime
- 2004-08-30 US US11/630,446 patent/US9044473B2/en active Active
- 2004-08-30 PL PL04782579.9T patent/PL1673104T5/pl unknown
- 2004-08-30 JP JP2006524936A patent/JP5819574B2/ja not_active Expired - Lifetime
- 2004-08-30 EP EP04782579.9A patent/EP1673104B2/en not_active Expired - Lifetime
- 2004-08-30 CA CA2537238A patent/CA2537238C/en not_active Expired - Lifetime
- 2004-08-30 AU AU2004268645A patent/AU2004268645B2/en not_active Expired
2012
- 2012-02-17 US US13/399,787 patent/US9089566B2/en not_active Expired - Lifetime
2014
- 2014-01-09 CY CY20141100019T patent/CY1114815T1/el unknown
2015
- 2015-02-05 US US14/615,098 patent/US9572870B2/en not_active Expired - Fee Related
2017
- 2017-01-06 US US15/400,289 patent/US11040088B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20120148558A1 (en)	2012-06-14
CA2537238A1 (en)	2005-03-10
DK1673104T4 (da)	2022-01-17
JP2007504166A (ja)	2007-03-01
EP1673104A2 (en)	2006-06-28
ES2441612T5 (es)	2022-04-04
US9572870B2 (en)	2017-02-21
US20170182134A1 (en)	2017-06-29
CA2537238C (en)	2015-01-06
SI1673104T1 (sl)	2014-02-28
US11040088B2 (en)	2021-06-22
US7442372B2 (en)	2008-10-28
CY1114815T1 (el)	2016-12-14
AU2004268645B2 (en)	2010-02-18
AU2004268645A1 (en)	2005-03-10
ES2441612T3 (es)	2014-02-05
JP5819574B2 (ja)	2015-11-24
US9044473B2 (en)	2015-06-02
US20050048047A1 (en)	2005-03-03
SI1673104T2 (sl)	2022-01-31
PT1673104E (pt)	2014-01-15
EP1673104A4 (en)	2009-08-12
EP1673104B1 (en)	2013-10-09
US9089566B2 (en)	2015-07-28
US20090017005A1 (en)	2009-01-15
PL1673104T3 (pl)	2014-03-31
US20150150799A1 (en)	2015-06-04
WO2005021064A2 (en)	2005-03-10
EP1673104B2 (en)	2021-10-27
DK1673104T3 (da)	2014-01-20
WO2005021064A3 (en)	2005-08-25

Publication	Publication Date	Title
PT1673104E (pt)	2014-01-15	Distribuição de compostos terapêuticos ao cérebro e a outros tecidos
EP1638605A4 (en)	2009-08-12	DISTRIBUTION OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUE
EP1737453A4 (en)	2008-11-26	METHOD FOR THE USE OF IMMUNOMODULATORY COMPOUNDS AND COMPOSITIONS CONTAINING THEREOF FOR THE TREATMENT AND SUPPLY OF SKIN DISEASES OR DISORDERS
EP1567157A4 (en)	2008-06-25	METHODS OF USE AND COMPOSITIONS USING IMMUNOMODULATORY COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF MYELOPROLIFERATIVE SYNDROMES
AU2002341558A1 (en)	2003-04-01	Compositions and methods useful for non-invasive delivery of therapeutic molecules to the bloodstream
GB0324761D0 (en)	2003-11-26	Use of compounds in therapy
AU2003286741A8 (en)	2004-11-26	Methods and compositions for diagnosis and therapy of parkin-associated disorders
EP1680145A4 (en)	2007-05-23	METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEUROLOGICAL DISEASES
GB0305150D0 (en)	2003-04-09	Use of therapeutic compounds
IL173351A0 (en)	2006-06-11	Therapy of ocular disorders
PL373759A1 (pl)	2005-09-05	Nowe związki dihydropirymidynowe podstawione grupą cyjanową i ich zastosowanie do leczenia chorób
AU2003247140A1 (en)	2004-02-16	Delivering compounds to the brain by modifying properties of the bbb and cerebral circulation
PT1670482E (pt)	2014-03-12	Utilização de ciclesonida para o tratamento de doenças respiratórias
IL176227A0 (en)	2006-10-05	Compositions and methods of administering tubulin binding agents for the treatment of ocular diseases
GB0213869D0 (en)	2002-07-31	The treatment of pain
AU2003268484A8 (en)	2004-03-29	Delivery of therapeutics to the brain and spinal cord
AU2003255843A1 (en)	2004-03-11	1,3-thiazolin-4-ones as therapeutic compounds in the treatment of pain
IL164951A0 (en)	2005-12-18	The treatment of pain with lfendropil
GB0312844D0 (en)	2003-07-09	Use of compounds in medicine
GB0325957D0 (en)	2003-12-10	The treatment of pain
GB0322014D0 (en)	2003-10-22	The treatment of pain
IL174968A0 (en)	2008-04-13	The use of ifenprodil in the treatment of pain
GB0303533D0 (en)	2003-03-19	Delivery of agents to the body
HK1091752A (en)	2007-01-26	Specific delivery of drugs to the brain
GB0415267D0 (en)	2004-08-11	The treatment of pain